Bisphosphonates for Osteoporosis: The Drug Class Explained

What are bisphosphonates, and how do they work?

Bisphosphonates are a class of medicine used to treat and prevent osteoporosis, and they work by slowing down the natural breakdown of bone. The NHS explains that bisphosphonates "slow the rate that bone is broken down in your body," which "maintains bone density and reduces your risk of a broken bone" NHS.

Your skeleton is living tissue that constantly renews itself: some cells build new bone while others (called osteoclasts) break old bone down. In osteoporosis, breakdown outpaces building, so bone becomes thinner and more fragile. Bisphosphonates have a strong attraction to bone mineral — they are taken up into the skeleton at the sites where bone is being actively removed, and there they dampen the osteoclasts. The Royal Osteoporosis Society describes zoledronate, for example, as working "by slowing down the cells that break down bone," which "helps to restore the balance and make your bones stronger" Royal Osteoporosis Society.

Because they protect existing bone rather than rapidly rebuilding it, the benefit builds gradually. The NHS notes bisphosphonates "usually take 6 to 12 months to work" NHS — which is one reason they are taken consistently over years. They act on the imbalance behind bone loss, not its root causes, so understanding what causes osteoporosis still matters alongside treatment.

What are the main types of bisphosphonates in the UK?

There are four bisphosphonates commonly used for osteoporosis in the UK: alendronate, risedronate and ibandronate, usually taken as tablets, and zoledronate, given as a yearly infusion. NICE's guidance covers exactly these — "alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid" NICE TA464. Each is the same class of drug working the same way; the practical differences are how often you take them and how they suit your stomach and lifestyle.

• Alendronate (alendronic acid) is the one most people start on. For how to take it and its side effects in depth, see our full guide to alendronic acid.
• Risedronate (risedronic acid) is a tablet taken either daily or weekly, offered "particularly if you have a sensitive stomach or food pipe," because some people find it gentler on the digestive system than alendronate Royal Osteoporosis Society.
• Ibandronate (ibandronic acid) is "available as either tablets or injections" — a once-a-month tablet, or an injection given every three months. The Royal Osteoporosis Society describes the monthly tablet as "less frequent dosing than other bisphosphonates, making it more convenient for many people." It "isn't usually given as a first treatment," and is more often an option if you've already tried another bisphosphonate or others aren't suitable Royal Osteoporosis Society.
• Zoledronate (zoledronic acid) is different — it's "given as an intravenous infusion (IV or 'drip') once a year," usually at hospital Royal Osteoporosis Society.

Oral tablets vs the yearly infusion: what's the difference?

The oral bisphosphonates are tablets you take yourself with a strict routine; zoledronate is a once-a-year drip given by a clinician, with no daily or weekly routine to keep. The trade-off is convenience against how the medicine reaches your bones.

Tablets have to be taken carefully because bisphosphonates are poorly absorbed from the gut and can irritate the food pipe. The NHS rule is to "always take bisphosphonates on an empty stomach with a full glass of water," and to "stand or sit upright for 30 minutes" afterwards NHS — that 30-minute figure applies to the weekly or daily tablets (alendronate and risedronate). The once-monthly ibandronate tablet is stricter: the Royal Osteoporosis Society advises staying upright and taking nothing but plain water for a full hour (60 minutes) afterwards Royal Osteoporosis Society. The infusion bypasses all of that — the whole yearly dose goes straight into a vein. You may be offered zoledronate "if a drug treatment in tablet form isn't suitable for you, or if you have recently broken a hip." Before each infusion, the Royal Osteoporosis Society notes your doctor will recommend blood tests to check your calcium and vitamin D levels, and you may also have a test to make sure your kidneys are working well Royal Osteoporosis Society.

Who are bisphosphonates for?

Bisphosphonates are the first-line treatment for most people with osteoporosis, or at high risk of a fragility fracture. The Royal Osteoporosis Society calls them "the most common medicines" for osteoporosis, and says "alendronate (a bisphosphonate) is usually the first medicine that people are offered" Royal Osteoporosis Society.

NICE recommends them formally. Its guidance states that oral bisphosphonates (alendronic acid, ibandronic acid and risedronate sodium) and intravenous bisphosphonates (ibandronic acid and zoledronic acid) "are recommended, within their marketing authorisations, as options for treating osteoporosis in adults" who have been assessed as being at higher risk of a fragility fracture NICE TA464. That risk is often estimated with a tool like FRAX — our guide to fracture risk and FRAX explains how that works. NICE adds that the choice of treatment "should be made on an individual basis" between you and your clinician, weighing the advantages and disadvantages of each option NICE TA464.

What are the benefits of bisphosphonates?

The core benefit is fewer broken bones — bisphosphonates reduce the risk of the fractures that matter most in osteoporosis. NICE's review of the evidence "confirms that bisphosphonates are more effective at reducing the risk of fracture than placebo" NICE TA464. The Royal Osteoporosis Society puts it in everyday terms: risedronate, for instance, "can help to make your bones stronger and reduce your risk of broken bones, including hip and spinal fractures" Royal Osteoporosis Society.

For someone with thinning bones, that is the whole point — a hip or spinal fracture can be life-changing, and reducing that risk is what treatment is for. If you're wondering how much bone can actually be regained, our guide to whether osteoporosis can be reversed looks at the evidence.

What are the side effects of bisphosphonates?

Most people tolerate bisphosphonates well; the common effects differ between the tablets and the infusion, and the serious risks are rare. It helps to separate them.

Digestive effects (the tablets). The most common problems with oral bisphosphonates are irritation of the food pipe, swallowing problems and stomach pain — which is exactly why the upright, full-glass-of-water routine matters NHS.

A flu-like reaction (the infusion). After a zoledronate infusion, some people get a short-lived flu-like reaction — fever, chills, and muscle or joint aches. The Royal Osteoporosis Society notes this affects up to 3 in 10 people after the first infusion, usually settles within a couple of days, and is much less common after later doses Royal Osteoporosis Society.

Rare, serious effects (the whole class). Two rare risks are shared across bisphosphonates:

• Osteonecrosis of the jaw (ONJ) — delayed healing in the jaw, usually after dental work. The Royal Osteoporosis Society estimates it affects between 1 and 10 people in every 10,000 taking osteoporosis drug treatments Royal Osteoporosis Society. Keeping your teeth and gums healthy and telling your dentist you take a bisphosphonate are the main safeguards.
• Atypical thigh-bone (femoral) fractures — an unusual break linked with long-term use. To keep it in proportion: the Society notes that if 1,000 people were taking treatments linked to these fractures, "less than 1 person would have" one Royal Osteoporosis Society. New, unexplained thigh or groin pain should prompt a doctor's appointment.

What is a bisphosphonate "drug holiday"?

Bisphosphonates keep helping your bones for a while after you stop taking them, so after about five years some people are advised to pause — a break sometimes called a "drug holiday." The Royal Osteoporosis Society explains that "if you've been taking a bisphosphonate treatment for about five years, you may be advised to pause your treatment," usually for one to three years Royal Osteoporosis Society. The NHS similarly notes you "may need to take them for 5 years or longer," after which your doctor weighs up whether to continue NHS.

The reason a pause is even possible is that "bisphosphonates keep helping your bones for a while after you stop." The reason it is sometimes wanted is that the small risks tied to very long-term use, such as atypical thigh-bone fractures, are "linked with taking these treatments for many years" — and "some research shows that stopping treatment for a while may reduce your risk" Royal Osteoporosis Society. A holiday is a deliberate way to balance ongoing protection against those risks — not a sign of failure. Whether it's right for you depends on your own fracture risk and bone density, so it's a decision to make with your clinician.

How do bisphosphonates compare with denosumab?

Bisphosphonates and denosumab both slow bone breakdown and cut fracture risk, but they behave very differently once you stop. Denosumab (Prolia) is not a bisphosphonate — it's a twice-yearly injection that blocks a protein called RANKL. The Royal Osteoporosis Society draws the line clearly: "you can only pause treatment if you're taking a bisphosphonate," because denosumab does not keep helping your bones for a while after you stop Royal Osteoporosis Society. That's why there is no drug holiday with denosumab, and why stopping it without a planned follow-on can trigger a rapid "rebound" — the Society notes "some people have had several spinal fractures in the following months after they've stopped denosumab" Royal Osteoporosis Society. Our full guide to denosumab (Prolia) explains that contrast — and in fact, the follow-on treatment after denosumab is often a bisphosphonate. If you can't take or tolerate the tablets, that's frequently the fork in the road between the two approaches.

How do you know if a bisphosphonate is working?

You cannot feel your bones getting stronger, so the only way to know whether treatment is holding your bone density — and to inform any drug-holiday decision — is to measure it with a repeat bone scan. A bone density scan is normally repeated every two to five years, because bone density changes slowly and scans done too close together show little change Royal Osteoporosis Society. Because a pause-or-continue decision hinges on where your bone density actually stands, being able to track it over a course of treatment is genuinely useful.

That monitoring role is where a radiation-free approach fits. Standard DEXA uses a small X-ray dose; REMS (Radiofrequency Echographic Multi Spectrometry) is radiation-free, so it can be repeated safely to follow change over time. It complements — rather than replaces — your GP's or specialist's plan and any decision about staying on, pausing or switching treatment. You can book a radiation-free bone health assessment or learn more about our bone health assessment.

---

This article is for general information and is not a substitute for advice from your GP, pharmacist or specialist — never start, stop or change a prescribed medicine on your own. It is part of our bone health series; to understand the bigger picture, see what causes osteoporosis.